Olimersen and Irinotecan in Treating Patients With Metastatic or Recurrent Colorectal Cancer

Part of paid clinical trials in Cleveland, Ohio.

Sponsor
The University of Texas Health Science Center at San Antonio
Study ID
NCT00004870
Phase
PHASE1/PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Gene therapy such as oblimersen may make tumor cells more sensitive to chemotherapy drugs. Combining irinotecan and oblimersen may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of combining oblimersen and irinotecan in treating patients who have metastatic or recurrent colorectal cancer.

Key Dates

Start date
Jun 30, 2000
Status verified
Feb 2013
Primary completion
Sep 30, 2002
Completion
Sep 30, 2002

Study Design

Primary purpose
TREATMENT

Locations (3)

FacilityCityStateZIPSite coordinators
Ireland Cancer CenterClevelandOhio44106-5065-
Brooke Army Medical CenterFort Sam HoustonTexas78234-
San Antonio Cancer InstituteSan AntonioTexas78229-

Find similar trials in Cleveland, OH

By condition
Colorectal cancer
By specialty
OncologyGI oncology
By research site
Ireland Cancer Center· Cleveland, OHBrooke Army Medical Center· Fort Sam Houston, TXSan Antonio Cancer Institute· San Antonio, TX

Related Studies